If you want to give your investment portfolio a nice boost, then it could be worth considering the ASX shares listed below.
That's because they have been named as buys and tipped to rise materially from current levels. Here's what you need to know about them:
James Hardie Industries plc (ASX: JHX)
Analysts at Goldman Sachs see a lot of value in this building materials company's shares following a recent pullback.
The broker notes that it sees "upside from cyclical improvement and strategic execution against higher value product mix targets, which has scope to substantially improve group profitability." It also highlights that its analysts "continue to expect robust growth in FY26 as North America volumes accelerate to 7%, while new construction and PDG maintain momentum."
In light of this, the broker put a buy rating and $57.85 price target on its shares earlier this month. This implies a potential upside of almost 25% for investors over the next 12 months.
Neuren Pharmaceuticals Ltd (ASX: NEU)
The team at Bell Potter is feeling very bullish about this pharmaceuticals company and sees it as an ASX share to buy right now.
The broker was pleased with the phase two results from its NNZ-2591 trial in Pitt Hopkins syndrome. It highlights that NNZ-2591 "has now shown encouraging clinical data in two indications, each of which represent a similar if not larger market opportunity than Rett syndrome."
In addition, with no approved treatments available, it believes that "NNZ-2591 is comfortably in poll position to be the first drug to market."
In response to the news, the broker has retained its buy rating with an improved price target of $28.00. This implies a potential upside of almost 35% for investors from current levels.
Woodside Energy Group Ltd (ASX: WDS)
A third ASX share that could deliver big returns for investors according to analysts is energy giant Woodside.
Morgans thinks investors should be snapping up the company's shares while they are down in the dumps. It notes that "with the pullback in oil prices moderating and work at Scarborough back underway, we see now as a good time to add to positions."
This is particularly the case given its belief that Woodside "will still generate substantial high-quality earnings for years to come."
Morgans has an add rating and a $36.00 price target on its shares. This implies a potential upside of 31% for investors from current levels. In addition, the broker is forecasting dividend yields of 4%+ in both FY 2024 and FY 2025, boosting the total potential 12-month return to over 35%.
